Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter phase II study evaluating denosumab (XGEVA) in combination with nivolumab (OPDIVO) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squamous) with bone metastases

Trial Profile

A multicenter phase II study evaluating denosumab (XGEVA) in combination with nivolumab (OPDIVO) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squamous) with bone metastases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs Denosumab (Primary) ; Nivolumab (Primary)
  • Indications Bone metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms DENIVOS
  • Most Recent Events

    • 14 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 12 Sep 2018 Status changed from recruiting to not yet recruiting.
    • 01 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top